The VERITAS Trial and the Future of Transthoracic Biopsy: A Call to Action for Radiologists

The VERITAS trial challenges the long-held superiority of transthoracic needle biopsy (TTNB) for peripheral lung nodules by showing noninferior diagnostic yield with navigational bronchoscopy. However, underuse of rapid on-site evaluation (ROSE) in the TTNB arm likely disadvantaged its performance. This Viewpoint contextualizes VERITAS, underscores the ongoing importance of TTNB, and calls radiologists to action-integrating ROSE, innovating procedural safety, and engaging in multidisciplinary decision-making to sustain radiology's leadership in lung cancer diagnosis.

Authors

Institutions

Publication Details

Journal
American Journal of Roentgenology
Published
2025-11-26
DOI
https://doi.org/10.2214/ajr.25.34133
Citations
1
Primary Topic
Lung Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
1.52
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The VERITAS Trial and the Future of Transthoracic Biopsy: A Call to Action for Radiologists

Peter R. Gunderman
1 citations
American Journal of Roentgenology
Lung Cancer Diagnosis and Treatment
1.52
article

The VERITAS Trial and the Future of Transthoracic Biopsy: A Call to Action for Radiologists

Peter R. Gunderman
article en
1 citations

Abstract

The VERITAS trial challenges the long-held superiority of transthoracic needle biopsy (TTNB) for peripheral lung nodules by showing noninferior diagnostic yield with navigational bronchoscopy. However, underuse of rapid on-site evaluation (ROSE) in the TTNB arm likely disadvantaged its performance. This Viewpoint contextualizes VERITAS, underscores the ongoing importance of TTNB, and calls radiologists to action-integrating ROSE, innovating procedural safety, and engaging in multidisciplinary decision-making to sustain radiology's leadership in lung cancer diagnosis.

American Journal of Roentgenology
Indiana University School of Medicine, Indiana University – Purdue University Indianapolis (US)
Openalex Percentile: Top 13%
Lung Cancer Diagnosis and Treatment
1.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.